PPARG and fatty liver disease: According to our data, in contrast to RSG, INT131 did not exacerbate hepatic hypertrophy and hepatic steatosis and exerted reduced effects on the hepatic expression of adipogenic and lipogenic genes, consistently with the phenotype observed in genetic PPARγ liver-null mice and further indicating INT131 did not stimulate PPARγ activation in the liver.